The development of a theory informed behaviour change intervention to improve adherence to dietary and physical activity treatment guidelines in individuals with familial hypercholesterolaemia (FH)

[1] Wong B(2016)Cardiovascular disease risk associated with familial hypercholesterolemia: a systematic review of the literature Clin Ther 38 1696-1709

[2] Kruse G(2017)Incidence of various types of atherosclerotic disease in patients with genotyped familial hypercholesterolemia Atherosclerosis 263 e26-416

[3] Kutikova L(2018)Roeters van Lennep JE. Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy J Clin Lipidol 12 409-255

[4] Ray KK(2017)Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis BMJ Open 7 e016461-15

[5] Mata P(2018)Overview of the current status of familial hypercholesterolaemia care in over 60 countries - the EAS familial Hypercholesterolaemia studies collaboration (FHSC) Atherosclerosis. 277 234-30

[6] Bruckert E(2019)Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: a cohort study Atherosclerosis 287 8-2381

[7] Retterstol K(2017)Predicting Cardiovascular Events in Familial Hypercholesterolemia Circulation 135 2133-3058

[8] Mundal L(2019)Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis Journal of Clinical Lipidology 13 15-43

[9] Igland J(2019)2019 ACC/AHA guideline on the primary prevention of cardiovascular disease Circulation 0 CIR.0000000000000678-103

[10] Seppola Tell G(2016)2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur Heart J 37 2315-172

[1] Wong B(2016)Cardiovascular disease risk associated with familial hypercholesterolemia: a systematic review of the literature Clin Ther 38 1696-1709

[2] Kruse G(2017)Incidence of various types of atherosclerotic disease in patients with genotyped familial hypercholesterolemia Atherosclerosis 263 e26-416

[3] Kutikova L(2018)Roeters van Lennep JE. Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy J Clin Lipidol 12 409-255

[4] Ray KK(2017)Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis BMJ Open 7 e016461-15

[5] Mata P(2018)Overview of the current status of familial hypercholesterolaemia care in over 60 countries - the EAS familial Hypercholesterolaemia studies collaboration (FHSC) Atherosclerosis. 277 234-30

[6] Bruckert E(2019)Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: a cohort study Atherosclerosis 287 8-2381

[7] Retterstol K(2017)Predicting Cardiovascular Events in Familial Hypercholesterolemia Circulation 135 2133-3058

[8] Mundal L(2019)Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis Journal of Clinical Lipidology 13 15-43

[9] Igland J(2019)2019 ACC/AHA guideline on the primary prevention of cardiovascular disease Circulation 0 CIR.0000000000000678-103

[10] Seppola Tell G(2016)2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur Heart J 37 2315-172